NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 124
(Total Views: 93)
Posted On: 12/20/2024 4:06:23 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Committed to Ensuring Highest Standards in Continued Buntanetap Trials
Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases. The company’s lead candidate, buntanetap, is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression. A recent article highlights the company’s successful clinical trials and its receipt of FDA clearance to proceed with a pivotal phase 3 Alzheimer’s disease program for buntanetap, set to begin in early 2025.
“Our priority is to bring a safe and effective treatment to patients, and we are committed to ensuring the next clinical trials are executed at the highest standards to attain an expedited NDA submission,” Dr. Maccecchini said in a recent episode of IBNs’ BioMedWire Podcast.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases. The company’s lead candidate, buntanetap, is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression. A recent article highlights the company’s successful clinical trials and its receipt of FDA clearance to proceed with a pivotal phase 3 Alzheimer’s disease program for buntanetap, set to begin in early 2025.
“Our priority is to bring a safe and effective treatment to patients, and we are committed to ensuring the next clinical trials are executed at the highest standards to attain an expedited NDA submission,” Dr. Maccecchini said in a recent episode of IBNs’ BioMedWire Podcast.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
(0)
(0)